Papanicolaou smears are of little value in the post-treatment surveillance of patients with ovarian epithelial cancer

Journal of Lower Genital Tract Disease

Volumn 5, Issue 3, 2001, Pages 130-132

  Patsner, B ^a  

^a NONE   (United States)

Author keywords

Ovarian cancer; Pap smear; Surveillance

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN;

ARTICLE; CANCER RECURRENCE; CANCER STAGING; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; EPITHELIUM; FEMALE; FEMALE GENITAL TRACT CYTOLOGY; GOOD CLINICAL PRACTICE; GYNECOLOGIC SURGERY; HEALTH CARE COST; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; OVARY ADENOCARCINOMA; OVARY CANCER; PAPANICOLAOU TEST; POSTOPERATIVE CARE; SCREENING TEST;

EID: 0035211167     PISSN: 10892591     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-0976.2001.53003.x     Document Type: Article

References (8)

1. Inadequacy of Papanicolaou smears in the detection of endometrial cancer
2. Extrauterine malignancies: Role of Pap smears in diagnosis and management
3. Primary peritoneal carcinoma presenting on routine Papanicolaou smear
4. Atypical presentation of microscopically advanced ovarian carcinoma
5. Risk of endometrial, ovarian, vulvar, and vaginal cancers after a positive cervical cytology followed by negative histology
6. Recurrences of gynecologic malignancy at the vaginal vault after hysterectomy